MDXG — what changed in the latest 10-Q
A section-by-section comparison of MDXG's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-29 vs the prior 10-Q · 2026-04-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +44 | −19 | ~11 | 7 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 11 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 11 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 11 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 11 |
| Other information | No paragraph-level changes | 0 | 0 | 0 | 10 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-29
During the second quarter of 2026, we continued to execute our strategic priorities, including expanding our Surgical portfolio, launching new products, advancing recent cost reduction initiatives, and returning capital to shareholders through our Share Repurchase Plan. These efforts contributed to …
•Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales. Surgical growth was driven by continued adoption of AMNIOFIX®, AMNIOEFFECT®, and our particulate portfolio, as well as contribut…
•We reported a GAAP net loss of $15 million or $0.10 per diluted share, and ended the quarter with $136 million of cash and cash equivalents.
•During the quarter, we completed a reduction-in-force and implemented additional cost reduction initiatives designed to align our cost structure with current business needs and support operating efficiency.
•Separately, we repurchased approximately $13 million of common stock under our Share Repurchase Plan, reflecting our continued commitment to disciplined capital allocation and delivering long-term shareholder value.
Text removed vs the prior filing · source: 10-Q · 2026-04-29
During the first quarter of 2026, the Company delivered the following financial results:
•Net sales of $59 million, reflecting a 33% decrease over the prior year period. which was comprised of:
◦Surgical net sales of $36 million, reflecting an increase of 13% compared to the prior year period; and
◦Wound net sales of $23 million, reflecting a decrease of 60% compared to the prior year period
•GAAP net loss and net loss margin for the first quarter of 2026 of $11 million and 18%, respectively.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice